XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Fair Value Measurements | 9 Months Ended
--- | ---
Apr. 30, 2024
Fair Value Disclosures [Abstract] |
Fair Value Measurements | Note 8—Fair Value Measurements The following table presents the balance of assets and liabilities measured at fair value on a recurring basis: Schedule of Balance of Assets Measured at Fair Value on a Recurring Basis
|  | Level 1 (1) |  |  | Level 2 (2) |  |  | Level 3 (3) |  |  | Total |
|  | (in thousands) |
April 30, 2024 |  |  |  |  |  |  |  |  |  |  |  |
Debt securities |  | $ | 23,579 |  |  | $ | 5,805 |  |  | $ | — |  |  | $ | 29,384 |
Equity investments included in current assets |  |  | 4,844 |  |  |  | — |  |  |  | — |  |  |  | 4,844 |
Equity investments included in noncurrent assets |  |  | — |  |  |  | 500 |  |  |  | 1,425 |  |  |  | 1,925 |
Total |  | $ | 28,423 |  |  | $ | 6,305 |  |  | $ | 1,425 |  |  | $ | 36,153 |
Acquisition consideration included in: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other current liabilities |  | $ | — |  |  | $ | — |  |  | $ | (190 | ) |  | $ | (190 | )
Other noncurrent liabilities |  |  | — |  |  |  | — |  |  |  | (2,722 | ) |  |  | (2,722 | )
Total |  | $ | — |  |  | $ | — |  |  | $ | (2,912 | ) |  | $ | (2,912 | )
July 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt securities |  | $ | 31,038 |  |  | $ | 11,376 |  |  | $ | — |  |  | $ | 42,414 |
Equity investments included in current assets |  |  | 6,198 |  |  |  | — |  |  |  | — |  |  |  | 6,198 |
Equity investments included in noncurrent assets |  |  | — |  |  |  | 2,500 |  |  |  | 1,263 |  |  |  | 3,763 |
Total |  | $ | 37,236 |  |  | $ | 13,876 |  |  | $ | 1,263 |  |  | $ | 52,375 |
Acquisition consideration included in: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other current liabilities |  | $ | — |  |  | $ | — |  |  | $ | (2,032 | ) |  | $ | (2,032 | )
Other noncurrent liabilities |  |  | — |  |  |  | — |  |  |  | (2,773 | ) |  |  | (2,773 | )
Total |  | $ | — |  |  | $ | — |  |  | $ | (4,805 | ) |  | $ | (4,805 | )
(1) | – quoted prices in active markets for identical assets or liabilities
(2) | – observable inputs other than quoted prices in active markets for identical assets and liabilities
(3) | – no observable pricing inputs in the market
At April 30, 2024 and July 31, 2023, the Company had $2.9 million and $3.0 million, respectively, in investments in hedge funds, which were included in noncurrent “Equity investments” in the accompanying consolidated balance sheets. The Company’s investments in hedge funds were accounted for using the equity method, therefore they were not measured at fair value. The following table summarizes the change in the balance of the Company’s assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3): Schedule of Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | Three Months Ended April 30, |  |  | Nine Months Ended April 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | (in thousands) |
Balance, beginning of period |  | $ | 1,450 |  |  | $ | 1,225 |  |  | $ | 1,263 |  |  | $ | 1,132 |
Total (losses) gains included in “Other expense, net” |  |  | (25 | ) |  |  | 13 |  |  |  | 162 |  |  |  | 106 |
Balance, end of period |  | $ | 1,425 |  |  | $ | 1,238 |  |  | $ | 1,425 |  |  | $ | 1,238 |
Change in unrealized gains or losses for the period included in earnings for assets held at the end of the period |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
The following table summarizes the change in the balance of the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3): Schedule of Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)
|  | Three Months Ended April 30, |  |  | Nine Months Ended April 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | (in thousands) |
Balance, beginning of period |  | $ | 4,517 |  |  | $ | 6,609 |  |  | $ | 4,805 |  |  | $ | 8,546 |
Payments |  |  | (1,650 | ) |  |  | (1,800 | ) |  |  | (1,864 | ) |  |  | (2,175 | )
Total losses (gains) included in: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
“Other operating expense, net” |  |  | — |  |  |  | 216 |  |  |  | (73 | ) |  |  | (1,349 | )
Interest expense included in “Interest income, net” |  |  | 45 |  |  |  | 97 |  |  |  | 45 |  |  |  | 97 |
“Foreign currency translation adjustment” |  |  | — |  |  |  | 2 |  |  |  | (1 | ) |  |  | 5 |
Balance, end of period |  | $ | 2,912 |  |  | $ | 5,124 |  |  | $ | 2,912 |  |  | $ | 5,124 |
Change in unrealized gains or losses for the period included in earnings for liabilities held at the end of the period |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
In the nine months ended April 30, 2024 and 2023, the Company paid an aggregate of $1.9 million and $2.2 million, respectively, for contingent consideration related to prior acquisitions, which, in the nine months ended April 30, 2024, included 2,679 shares of the Company’s Class B common stock with an issue date value of $0.1 million. In addition, in January 2024, the Company determined that the requirement for a contingent consideration payment related to an acquisition in a prior period would not be met, and, in September 2022, the Company determined that the requirements for a portion of the contingent consideration payments related to the Leaf acquisition would not be met. The Company recognized gains of $0.1 million and $1.6 million in the nine months ended April 30, 2024 and 2023, respectively, on the write-off of these contingent consideration payment obligations. Also, in the three and nine months ended April 30, 2023, the Company increased the estimated fair value of acquisition-related contingent consideration by $0.2 million. These write-offs of contingent consideration net of the increase in the contingent consideration were included in “Other operating expense, net” in the accompanying consolidated statements of income. Fair Value of Other Financial Instruments The estimated fair value of the Company’s other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. Cash and cash equivalents, restricted cash and cash equivalents, settlement assets, other current assets, customer deposits, settlement liabilities, and other current liabilities. At April 30, 2024 and July 31, 2023, the carrying amount of these assets and liabilities approximated fair value because of the short period of time to maturity. The fair value estimates for cash, cash equivalents, and restricted cash and cash equivalents were classified as Level 1 and settlement assets, other current assets, customer deposits, settlement liabilities, and other current liabilities were classified as Level 2 of the fair value hierarchy. Other assets and other liabilities. At April 30, 2024 and July 31, 2023, the carrying amount of these assets and liabilities approximated fair value. The fair values were estimated based on the Company’s assumptions, which were classified as Level 3 of the fair value hierarchy.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration